Jack O Egan
Overview
Explore the profile of Jack O Egan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
996
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shrestha N, Chaturvedi P, Zhu X, Dee M, George V, Janney C, et al.
Aging Cell
. 2023 Mar;
22(5):e13806.
PMID: 36967480
Accumulation of senescent cells (SNCs) with a senescence-associated secretory phenotype (SASP) has been implicated as a major source of chronic sterile inflammation leading to many age-related pathologies. Herein, we provide...
2.
Zhu X, Li Q, George V, Spanoudis C, Gilkes C, Shrestha N, et al.
Front Immunol
. 2023 Feb;
14:1114802.
PMID: 36761778
Atherosclerosis is a chronic inflammatory disease caused by deposition of oxidative low-density lipoprotein (LDL) in the arterial intima which triggers the innate immune response through myeloid cells such as macrophages....
3.
Becker-Hapak M, Shrestha N, McClain E, Dee M, Chaturvedi P, Leclerc G, et al.
Cancer Immunol Res
. 2021 Jul;
9(9):1071-1087.
PMID: 34244297
Natural killer (NK) cells are a promising cellular therapy for cancer, with challenges in the field including persistence, functional activity, and tumor recognition. Briefly, priming blood NK cells with recombinant...
4.
Liu B, Zhu X, Kong L, Wang M, Spanoudis C, Chaturvedi P, et al.
Mol Ther
. 2021 Jun;
29(10):2949-2962.
PMID: 34091051
Advances in immunostimulatory and anti-immunosuppressive therapeutics have revolutionized cancer treatment. However, novel immunotherapeutics with these dual functions are not frequently reported. Here we describe the creation of a heterodimeric bifunctional...
5.
Margolin K, Morishima C, Velcheti V, Miller J, Lee S, Silk A, et al.
Clin Cancer Res
. 2018 Jul;
24(22):5552-5561.
PMID: 30045932
IL15 induces the activation and proliferation of natural killer (NK) and memory CD8 T cells and has preclinical antitumor activity. Given the superior activity and favorable kinetics of ALT-803 (IL15N72D:IL15RαSu/IgG1...
6.
Wrangle J, Velcheti V, Patel M, Garrett-Mayer E, Hill E, Ravenel J, et al.
Lancet Oncol
. 2018 Apr;
19(5):694-704.
PMID: 29628312
Background: Immunotherapy with PD-1 or PD-L1 blockade fails to induce a response in about 80% of patients with unselected non-small cell lung cancer (NSCLC), and many of those who do...
7.
Romee R, Cooley S, Berrien-Elliott M, Westervelt P, Verneris M, Wagner J, et al.
Blood
. 2018 Feb;
131(23):2515-2527.
PMID: 29463563
New therapies for patients with hematologic malignancies who relapse after allogeneic hematopoietic cell transplantation (allo-HCT) are needed. Interleukin 15 (IL-15) is a cytokine that stimulates CD8 T-cell and natural killer...
8.
Ellis-Connell A, Balgeman A, Zarbock K, Barry G, Weiler A, Egan J, et al.
J Virol
. 2017 Nov;
92(3).
PMID: 29118125
Developing biological interventions to control human immunodeficiency virus (HIV) replication in the absence of antiretroviral therapy (ART) could contribute to the development of a functional cure. As a potential alternative...
9.
Rhode P, Egan J, Xu W, Hong H, Webb G, Chen X, et al.
Cancer Immunol Res
. 2015 Oct;
4(1):49-60.
PMID: 26511282
IL15, a potent stimulant of CD8(+) T cells and natural killer (NK) cells, is a promising cancer immunotherapeutic. ALT-803 is a complex of an IL15 superagonist mutant and a dimeric...
10.
Gomes-Giacoia E, Miyake M, Goodison S, Sriharan A, Zhang G, You L, et al.
PLoS One
. 2014 Jun;
9(6):e96705.
PMID: 24896845
Intravesical Bacillus Calmette-Guérin (BCG) has been shown to induce a specific immunologic response (i.e., activation of IL-2 and effector T-cells), while preclinical studies using ALT-803 (mutated IL-15 analogue combined with...